These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 9216839)

  • 21. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
    Shin HJ; Kim HJ; Kwak JH; Chun HO; Kim JH; Park H; Kim DH; Lee YS
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2313-6. PubMed ID: 12161123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
    Qiu Y; Kraft P; Lombardi E; Clancy J
    J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
    Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
    J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
    Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
    J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
    Haynes J; Killilea DW; Peterson PD; Thompson WJ
    J Pharmacol Exp Ther; 1996 Feb; 276(2):752-7. PubMed ID: 8632346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
    Vemulapalli S; Watkins RW; Chintala M; Davis H; Ahn HS; Fawzi A; Tulshian D; Chiu P; Chatterjee M; Lin CC; Sybertz EJ
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):862-9. PubMed ID: 8961086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase inhibitors.
    Boswell-Smith V; Spina D; Page CP
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
    Rybalkin SD; Bornfeldt KE
    Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats.
    Wilkes N; White S; Stein P; Bernie J; Rajasekaran M
    Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR; Hatzelmann A
    Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
    Picq M; Dubois M; Prigent AF; Némoz G; Pacheco H
    Biochem Int; 1989 Jan; 18(1):47-57. PubMed ID: 2541724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.
    Duarte J; Lugnier C; Torres AI; Pérez-Vizcaino F; Zarzuelo A; Tamargo J
    Gen Pharmacol; 1999 Jan; 32(1):71-4. PubMed ID: 9888257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The discovery of novel, potent and selective PDE5 inhibitors.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines.
    Suzuki H; Yamamoto M; Shimura S; Miyamoto K; Yamamoto K; Sawanishi H
    Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1163-8. PubMed ID: 12237530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.